Abstract: A process of producing an immunogenic particle includes mixing an aqueous solvent A wherein an antigen(s) is/are dissolved and a water-immiscible organic solvent B wherein an amphiphilic polymer(s) whose hydrophobic segment(s) is/are poly(hydroxy acid) is/are dissolved, to form a reversed-phase emulsion; and removing the solvent from the reversed-phase emulsion to obtain an antigen-adjuvant microparticle complex, wherein the aqueous solvent A and/or the water-immiscible organic solvent B contains a surfactant.
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
February 9, 2016
Date of Patent:
May 15, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.
Type:
Grant
Filed:
June 19, 2017
Date of Patent:
March 27, 2018
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: The disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based composition comprising; vegetable derived glycerine and an emulsifier. The emulsifier can be any known and/or commercially available glucoside containing substance. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may be added to impart desirable mechanical and physio-chemical properties. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture. The composition includes glycerine preferably present in the range of 50-95 weight %.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
March 13, 2018
Inventors:
Guerry L. Grune, William Wingfield, Martin E Oehlbeck
Abstract: A unit to treat inflammation of hemorrhoids, vulvo-vaginitis and similar conditions has a suppository and a multi-piece pad at a proximal end of the suppository. A first piece of the pad is adjacent the suppository so that medication can be applied concurrently to both. A second piece of the pad is a non-permeable layer disposed against the first piece. A third piece is an absorbent layer disposed against the second piece. A fourth piece is another non permeable layer disposed against the third piece. Medication from a container is applied to the unit through an adapter.
Abstract: The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
February 6, 2018
Assignees:
Consejo Superior De Investigaciones Cientificase (CSIC), Universidad De Sevilla
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
October 4, 2016
Date of Patent:
January 30, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Compositions and methods for repelling coffee berry borer. The compositions contain a substrate and a semiochemical capable of affecting the coffee berry borer intermixed within the substrate. The semiochemical may be verbenone.
Type:
Grant
Filed:
November 11, 2015
Date of Patent:
January 30, 2018
Inventors:
Agenor Mafra-Neto, Josue Isaias Ponce, William H Urrutia, Carmem R. Bernardi, Rodrigo Oliveira Da Silva
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
January 23, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
March 4, 2015
Date of Patent:
January 16, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
February 9, 2016
Date of Patent:
January 16, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
January 9, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
January 9, 2018
Assignees:
Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
Inventors:
Curtis Wright, Benjamin Oshlack, Christopher Breder
Abstract: The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by using an emulsification method, without involving the steps of chemical treatment of the surface of hydrogels or dilution, thereby facilitating mass production and preventing the decrease of drug encapsulation efficiency.
Type:
Grant
Filed:
October 12, 2011
Date of Patent:
December 26, 2017
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Eun Jung An, Do Hoon Kim, Hyung Jun Lim, Jong Won Shim, Choon Bok Jeong, Lee Kyoung Kwon, Jun Oh Kim
Abstract: The present invention relates to novel antiviral compounds which are covalently attached to solid, macro surfaces. In another embodiment, the invention relates to novel antiviral compositions including a polymeric material and, embedded therein, an antiviral compound. In other embodiments, the invention relates to making a surface antiviral and making a polymeric material antiviral.
Type:
Grant
Filed:
March 19, 2015
Date of Patent:
December 5, 2017
Assignees:
Research Foundation of the City University of New York, Long Island University, Pace University
Inventors:
Robert Engel, JaimeLee Iolani Rizzo, Karin Melkonian-Fincher
Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
November 28, 2017
Assignee:
CEDARS-SINAI MEDICAL CENTER
Inventors:
Rameshwar Patil, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
Abstract: Provided are an orally disintegrating tablet that quickly disintegrates when it is placed in the mouth or put into water, provides favorable taste, has a sufficient hardness in general production, transportation and use and is excellent in terms of storage stability, and a process for the production of the same which is excellent in terms of industrial production. An orally disintegrating tablet containing a drug, a crystalline cellulose having a bulk density of 0.23 g/cm3 or less (preferably from 0.10 g/cm3 to 0.23 g/cm3), a sugar alcohol and a pregelatinized starch.
Abstract: Medical constructs with collagen fibers and gelatin and related collagen fibers. The collagen fibers can be derived from extruded soluble dermal collagen and can include a gelatin film attached to the at least one collagen fiber. The gelatin film can include one or more minerals and has a gelatin concentration of between about 0.1% to about 40% weight per volume.
Type:
Grant
Filed:
October 5, 2015
Date of Patent:
October 31, 2017
Assignee:
MiMedx Group, Inc.
Inventors:
Leon Paulos, Mengyan Li, Daniel Hernandez, Thomas Koob
Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
Type:
Grant
Filed:
September 12, 2016
Date of Patent:
October 17, 2017
Assignee:
Children's Medical Center Corporation
Inventors:
Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
Abstract: An authenticable and machine readable coating for pills, tablets and other ingestible materials is provided. The disclosure also relates to methods of authenticating the same. The coatings are formed from a lattice of particles stacked to cause selective diffraction such that each pill or tablet has an optical signature. The signature associated with each coating can be read and authenticated. In one embodiment, the particles are substantially spherical and self-organized. In one embodiment, generally recognized as safe (GRAS) materials are used to form the particles.